Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Pacira Pharmaceuticals (DE:82P)
FRANKFURT:82P
RESEARCH TOOLSreports
Holding DE:82P?
Track your performance easily
82P Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€10.70 - €32.20
Previous Close€16.7
Volume0.00
Average Volume (3M)N/A
Market Cap
€777.81M
Enterprise Value€957.62M
Total Cash (Recent Filing)$453.81M
Total Debt (Recent Filing)$644.42M
Price to Earnings (P/E)―
Beta0.12
Next Earnings
Feb 27, 2025EPS Estimate
€0.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding46,173,240
10 Day Avg. Volume0
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)0.97
Price to Sales (P/S)1.11
Price to Cash Flow (P/CF)3.60
P/FCF Ratio3.50
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.38
Enterprise Value/Gross Profit1.95
Enterprise Value/Ebitda-64.08
Forecast
1Y Price Target
€19.74Price Target Upside18.21% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Pacira Pharmaceuticals News
PremiumCompany Announcements
Pacira BioSciences Reports Q3 2024 Earnings and Strategic Developments
PremiumCompany Announcements
Pacira Pharmaceuticals Faces Q3 Loss Amid Revenue GrowthBulls Say, Bears Say
Bulls Say
Financial PerformancePacira generated its second highest quarterly cash flow ever, indicating strong financial health.
Patent ProtectionThere is a decent probability of the patent ruling getting reversed on appeal, which could block generic competition until 2041 or lead to a legal settlement in the 2030s.
Strategic PartnershipsPCRX remains focused on ramping up Exparel use in anticipation of NOPAIN implementation and recently entered into another GPO partnership with Vizient that covers 30% of the Exparel market opportunity.
Bears Say
Earnings PerformanceOverall, 3Q24 results were unremarkable, which was expected given the focus on preparing for 2025.
Legal ChallengesLegal overhang will persist/limit multiple expansion.
Patent IssuesConcern about Exparel exclusivity following the patent invalidation which hit the stock.
---
Options Prices
Currently, No data available
---
Ownership Overview
1.55% Insiders
30.33% Mutual Funds
16.45% Other Institutional Investors
11.71% Public Companies and
Individual Investors
82P FAQ
What was Pacira Pharmaceuticals’s price range in the past 12 months?
Pacira Pharmaceuticals lowest stock price was €10.70 and its highest was €32.20 in the past 12 months.
What is Pacira Pharmaceuticals’s market cap?
Currently, no data Available
When is Pacira Pharmaceuticals’s upcoming earnings report date?
Pacira Pharmaceuticals’s upcoming earnings report date is Feb 27, 2025 which is in 96 days.
How were Pacira Pharmaceuticals’s earnings last quarter?
Pacira Pharmaceuticals released its earnings results on Nov 06, 2024. The company reported €0.754 earnings per share for the quarter, beating the consensus estimate of €0.672 by €0.082.
Is Pacira Pharmaceuticals overvalued?
According to Wall Street analysts Pacira Pharmaceuticals’s price is currently Undervalued.
Does Pacira Pharmaceuticals pay dividends?
Pacira Pharmaceuticals does not currently pay dividends.
What is Pacira Pharmaceuticals’s EPS estimate?
Pacira Pharmaceuticals’s EPS estimate is €0.75.
How many shares outstanding does Pacira Pharmaceuticals have?
Pacira Pharmaceuticals has 46,173,240 shares outstanding.
What happened to Pacira Pharmaceuticals’s price movement after its last earnings report?
Pacira Pharmaceuticals reported an EPS of €0.754 in its last earnings report, beating expectations of €0.672. Following the earnings report the stock price went up 1.235%.
Which hedge fund is a major shareholder of Pacira Pharmaceuticals?
Among the largest hedge funds holding Pacira Pharmaceuticals’s share is Gotham Asset Management LLC. It holds Pacira Pharmaceuticals’s shares valued at 1M.
---
Pacira Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€19.74 (18.21% Upside)
€19.74 (18.21% Upside)
Blogger Sentiment
Bullish
DE:82P Sentiment 100%
Sector Average 71%
Sector Average 71%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.24%
12-Months-Change
Fundamentals
Return on Equity
-11.48%
Trailing 12-Months
Asset Growth
-0.83%
Trailing 12-Months
Company Description
Pacira Pharmaceuticals
Pacira Biosciences, Inc. develops and manufactures injectable therapeutic products. The firm engages in the development, commercialization and manufacture of pharmaceutical products for use in postsurgical outcomes for acute care practitioners and their patients. Its flagship product, EXPAREL, redefines pain management after surgery as an opioid-free alternative indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The company was founded in December 2006 and is headquartered in Parsippany, NJ.
---
82P Earnings Call
Q3 2024
0:00 / 0:00
---
82P Stock 12 Month Forecast
Average Price Target
€19.74
▲(18.21% Upside)
Technical Analysis
Pacira Pharmaceuticals
―
Supernus Pharmaceuticals
―
Axsome Therapeutics
―
Dr Reddy's Laboratories
―
ACADIA Pharmaceuticals
―
Best Analysts Covering 82P
1 Year
1 Year Success Rate
12/40 ratings generated profit
1 Year Average Return
-9.20%
reiterated a buy rating 17 days ago
Copying Oren Livnat's trades and holding each position for 1 Year would result in 30.00% of your transactions generating a profit, with an average return of -9.20% per trade.
---